Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.
about
The Effect of Additives on the Behavior of Phase Sensitive In Situ Forming Implants.Liquid-solid phase-inversion PLGA implant for the treatment of residual tumor tissue after HIFU ablation.Effect of cargo properties on in situ forming implant behavior determined by noninvasive ultrasound imaging.Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imagingNoninvasive characterization of in situ forming implants using diagnostic ultrasound.Amphiphilic Interpenetrating Networks for the Delivery of Hydrophobic, Low Molecular Weight Therapeutic Agents.pH-Responsive Hydrogels with Dispersed Hydrophobic Nanoparticles for the Delivery of Hydrophobic Therapeutic AgentsAdvances in image-guided intratumoral drug delivery techniques.An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot SystemsEffect of injection site on in situ implant formation and drug release in vivo.Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation.Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure.Increasing Distribution of Drugs Released from In Situ Forming PLGA Implants Using Therapeutic Ultrasound.Quality by design approach to optimize the formulation variables influencing the characteristics of biodegradable intramuscular in-situ gel loaded with alendronate sodium for osteoporosis.
P2860
Q30373324-B335CA26-96F5-4EB7-A959-CE41EDF282B2Q30417350-4DA1B8D0-7F26-4D2F-9AEB-0FC1E99D6664Q30458569-A31D1D3C-5638-4566-9141-F102156FF5CCQ30460008-6CA631AB-A6B7-4741-8AD3-3F0AD17008EBQ30475791-64A0C936-A5AB-43AD-A1D9-9141188200E0Q35661757-B8E85732-0110-428D-A3B3-110DE928A647Q36327202-10460857-0227-466A-9118-E3525D84443EQ38027851-9514A21C-BFE9-4A37-93DC-CA3F3919B4E7Q39419942-ACC8D8BD-42AC-48F7-8273-553F61CEE620Q39664876-314E08D8-CDC9-450C-8FA9-1FA243D569F6Q40014643-E6383C57-09B6-449E-9B19-6267CD4F6131Q42677388-EAFA0779-85D8-4DF0-A056-26F9B7970DC3Q47656366-066577F0-DB37-431A-A7B4-7F832C5F4860Q55180776-36B0091D-978D-4389-AEC1-114673D89D03
P2860
Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Characterization of formulatio ...... forming drug delivery systems.
@en
Characterization of formulatio ...... forming drug delivery systems.
@nl
type
label
Characterization of formulatio ...... forming drug delivery systems.
@en
Characterization of formulatio ...... forming drug delivery systems.
@nl
prefLabel
Characterization of formulatio ...... forming drug delivery systems.
@en
Characterization of formulatio ...... forming drug delivery systems.
@nl
P2093
P2860
P356
P1476
Characterization of formulatio ...... forming drug delivery systems.
@en
P2093
Angela N Carlson
Luis Solorio
Ravi B Patel
P2860
P304
P356
10.1002/JBM.A.32724
P577
2010-08-01T00:00:00Z